Publications
Popescu B, Jones MF, Piao M, Tran E, Koh A, Lomeli I, Peretz CAC, Murad N, Abelson S, Morales C, Rivera JM, Batingana AR, D'Souza J, Pikman Y, Cheng ML, Logan AC, Huang BJ, Stieglitz E, Smith CC. Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML. Blood. 2026. PMID: 41144772
Popescu B, Jones MF, Piao M, Tran E, Koh A, Lomeli I, Peretz CAC, Murad N, Abelson S, Morales C, Rivera JM, Batingana AR, D'Souza J, Pikman Y, Cheng ML, Logan AC, Huang BJ, Stieglitz E, Smith CC. Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML. Blood. 2026. PMID: 41144772
Popescu B, Jones MF, Piao M, Tran E, Koh A, Lomeli I, Peretz CAC, Murad N, Abelson S, Morales C, Rivera JM, Batingana AR, D'Souza J, Pikman Y, Cheng ML, Logan AC, Huang BJ, Stieglitz E, Smith CC. Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML. Blood. 2026. PMID: 41144772
Valtis YK, Lin C, Nemirovsky D, Devlin S, Rejeski K, Curran KJ, Wang X, Shah NN, Jeyakumar N, Miller K, Zhang A, Kota VK, Al Darobi AH, Muhsen I, Sasine J, Aldoss I, Advani AS, Reshef R, Chen EC, Kopmar N, Tsai SB, Hilal T, Shah BD, Faramand R, Solh MM, Tan V, Bezerra E, Battiwalla M, Ramakrishnan A, Mathews J, Shaughnessy P, Mountjoy L, Hoeg RT, Dykes KC, Logan AC, Kumaran MV, Schwartz M, Tracy S, Moore J, Odstrcil Bobillo S, Frey NV, Connor M, Ladha A, Dholaria B, Sutherland K, Roloff GW, Muffly LS, Park JH. CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia. Blood advances. 2026. PMID: 41052404
Valtis YK, Lin C, Nemirovsky D, Devlin S, Rejeski K, Curran KJ, Wang X, Shah NN, Jeyakumar N, Miller K, Zhang A, Kota VK, Al Darobi AH, Muhsen I, Sasine J, Aldoss I, Advani AS, Reshef R, Chen EC, Kopmar N, Tsai SB, Hilal T, Shah BD, Faramand R, Solh MM, Tan V, Bezerra E, Battiwalla M, Ramakrishnan A, Mathews J, Shaughnessy P, Mountjoy L, Hoeg RT, Dykes KC, Logan AC, Kumaran MV, Schwartz M, Tracy S, Moore J, Odstrcil Bobillo S, Frey NV, Connor M, Ladha A, Dholaria B, Sutherland K, Roloff GW, Muffly LS, Park JH. CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia. Blood advances. 2026. PMID: 41052404
Jang A, Jindal T, Khaki AR, Jiang CY, Alhalabi O, Nguyen CB, Tsung I, Oh E, Epstein I, Bakaloudi DR, Jaime-Casas S, Nizam A, Glover M, Mabey H, Taylor A, Evans S, Shin D, Pywell C, Abuqayas B, Barata PC, Zakharia Y, Basu A, Kilari D, Bilen MA, Emamekhoo H, Milowsky M, Hoimes CJ, Davis N, Shah S, Gupta S, Tripathi A, Grivas P, Bellmunt J, Alva A, Campbell MT, Chen Z, Fu P, Koshkin VS, Brown JR. Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database. Clinical genitourinary cancer. 2026. PMID: 41644316
So J, Droznin AD, Tiwari P, Chen YH, Chau NG, Margalit DN, Tishler RB, Hanna GJ, Mak RH, Fitzgerald KJ, Sehgal K, Li S, Gunasti L, Kim E, Minken J, Baginska J, Nau A, Diaz IG, Shim B, Janes JT, Uppaluri R, Haddad RI, Livak KJ, Schoenfeld JD. Stereotactic Body Radiation Therapy With Pembrolizumab in Programmed Cell Death Protein 1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial. International journal of radiation oncology, biology, physics. 2026. PMID: 41520892
Jabbour E, Sandhu KS, Shaughnessy P, Logan AC, Abedi M, Shah BD, Bishop MR, Park JH, DeAngelo DJ, Tholouli E, Yallop D, Chaganti S, Hodby K, Barba P, Guerreiro M, Menne T, Shang J, Lao-Sirieix P, Brugger W, Roddie C. Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Haematologica. 2026. PMID: 41504229
Jabbour E, Sandhu KS, Shaughnessy P, Logan AC, Abedi M, Shah BD, Bishop MR, Park JH, DeAngelo DJ, Tholouli E, Yallop D, Chaganti S, Hodby K, Barba P, Guerreiro M, Menne T, Shang J, Lao-Sirieix P, Brugger W, Roddie C. Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Haematologica. 2026. PMID: 41504229
Rugo HS, Tokunaga E, Iwata H, Petry V, Smit EF, Goto Y, Kim DW, Shitara K, Gruden JF, Modi S, Cortés J, Krop I, Jänne PA, Cheng Y, Taitt C, Cheng FC, Powell CA. Erratum to 'Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis': [Annals of Oncology. Volume 36, Issue 11, November 2025, Pages 1389-1399]. Annals of oncology : official journal of the European Society for Medical Oncology. 2026. PMID: 41506947
Huynh DJ, Luce CS, Shah N, Duong N. Association between erectile dysfunction and cirrhosis severity: a 9-year real-world data analysis. The journal of sexual medicine. 2026. PMID: 41521672
Kenfield SA, Hart NH, Courneya KS, Greenwood R, Chan JM, Sison J, Zhang L, Rudman S, Ung L, Schumann M, Van Blarigan EL, McKeown S, Ryan CJ, Catto J, Galvão DA, Newton RU, Saad F, INTERVAL-GAP4 Site Investigators and INTERVAL-GAP4 Steering and Management Committees. Feasibility and Implementation of INTERVAL-GAP4: A Global Randomised Controlled Trial of Intense Hybrid-supervised/Self-managed Versus Self-directed Exercise for Metastatic Prostate Cancer. European Urology Open Science. 2026. PMID: 41561488
Piscitello G, Ma JE, Shah N, Schenker Y, Eckert E, Odom DC, Nouri S, Rabow MW, Sudore RL, Gonzales MJ, Kross EK, Merel SE, Arnold RM, Casarett D, Schell J. Differences in Goals of Care and Advance Care Planning Note Templates. Journal of pain and symptom management. 2026. PMID: 41512974
Glatt T, Leggat-Barr K, Seth N, Heditsian D, van 't Veer L, Pusztai L, Price E, Hylton N, Formenti S, Rugo H, Fejerman L, Toriola AT, Fabian C, De Censi A, Grossman D, Olopade O, Jackson A, Horton S, Rhoads K, Lange C, Borges V, Garner E, Garber J, Yee D, Esserman L. RISE UP for breast cancer 2024: conference highlights & takeaways. Breast cancer research and treatment. 2026. PMID: 41493489
Rugo HS, Kaklamani V, McArthur H, Wander SA, Gradishar W, Mahtani R, Pegram M, Lustberg M, Swallow E, Maitland J, Kloss S, Wasserman T, Tolaney SM. Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 41235919
Vincken R, Pasco ST, Steri V, Bozal-Basterra L, van IJcken WFJ, Carracedo A, Huylebroeck D, Moasser MM, Ruiz-Sáenz A. Metabolic alterations driven by PFKFB3 upregulation confer resistance to trastuzumab in HER2-positive breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2026. PMID: 41496324
Hicks LK, Messersmith HJ, Al Hadidi S, Banerjee R, Derman BA, Kumar S, Wildes TM, Bal S, Bhella S, Chmielewski C, Costello C, Dabney R, Hartley-Brown M, Langerak A, Lipe B, Martin T, McCurdy A, Mian H, Riva E, Seth R, Subramanian L, Mikhael J. Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. PMID: 41494138
Truong AA, Ho S, Lee RH, Wu X, Kang H, El-Sayed IH, George JR, Heaton CM, Likhterov I, Xu MJ, Ha PK, Algazi AP, Wai KC. Perineural Invasion and Survival in Pembrolizumab-Treated Head and Neck Squamous Cell Carcinoma. The Laryngoscope. 2026. PMID: 41482826
Truong AA, Ho S, Lee RH, Wu X, Kang H, El-Sayed IH, George JR, Heaton CM, Likhterov I, Xu MJ, Ha PK, Algazi AP, Wai KC. Perineural Invasion and Survival in Pembrolizumab-Treated Head and Neck Squamous Cell Carcinoma. The Laryngoscope. 2026. PMID: 41482826
Mahadevan A, Vosooghi A, Arora JS, Kumar RS, Singh G, Tsai KK, Quandt Z. GLP- 1 Receptor Agonists in Patients with Cancer are Associated with Reduced All-Cause Mortality and Hospitalization. The Journal of clinical endocrinology and metabolism. 2026. PMID: 41482652